Antisense Therapeutics Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.
|Primary activities||The development of novel antisense pharmaceuticals for commercially important human conditions.|
|Industry / Sector||Drug Manufacturers—Specialty & Generic / Healthcare|
|Mailing address||14 Wallace Avenue Level 1 Toorak VIC 3142 Australia|
|Phone / Fax||61 3 9827 8999 / 61 3 9859 7701|
|Share registry||BOARDROOM PTY LIMITED|
Antisense Therapeutics does not pay dividends.
As of May 2021, following are the company executives and directors listed on Antisense Therapeutics.
|Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD||CEO, MD & Director||461.82k|
|Mr. Phillip Allen Hains||CFO & Joint Company Sec.||61||99k|
|Ms. Alicia Mellors||Joint Company Sec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Antisense Therapeutics is 94.72M and its enterprise value is 90.74M. The enterprise value to revenue ratio of ANP is 168.64.
The ANP's stocks Beta value is 0.92 making it 8% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Antisense Therapeutics (ANP)
Antisense Therapeutics (ASX:ANP) Frequently Asked Questions
1. What is Antisense Therapeutics's Stock Symbol?
Antisense Therapeutics trades on ASX under the ticker symbol "ANP".
2. What is Antisense Therapeutics's stock price today?
One share of ANP stock can currently be purchased for approximately $0.165.
3. How can I contact Antisense Therapeutics?
Antisense Therapeutics's mailing address is 14 Wallace Avenue Level 1 Toorak VIC 3142 Australia. The company can be reached via phone at 61 3 9827 8999.
4. What is Antisense Therapeutics's official website?
The official website of Antisense Therapeutics is http://www.antisense.com.au.
5. Which share registry manages Antisense Therapeutics's stock?
Antisense Therapeutics's stock is managed by BOARDROOM PTY LIMITED.